Impact of Renal Impairment on Beta-Blocker Efficacy in Patients With Heart Failure

被引:51
作者
Kotecha, Dipak [1 ,2 ]
Gill, Simrat K. [1 ]
Flather, Marcus D. [3 ]
Holmes, Jane [4 ]
Packer, Milton [5 ]
Rosano, Giuseppe [6 ,7 ]
Boehm, Michael [8 ]
McMurray, John J. V. [9 ,10 ]
Wikstrand, John [11 ]
Anker, Stefan D. [12 ]
van Veldhuisen, Dirk J. [13 ]
Manzano, Luis [14 ]
von Lueder, Thomas G. [2 ,15 ]
Rigby, Alan S. [16 ]
Andersson, Bert [17 ,18 ]
Kjekshus, John [19 ,20 ]
Wedel, Hans [21 ]
Ruschitzka, Frank [22 ]
Cleland, John G. F. [23 ]
Damman, Kevin [13 ]
Redon, Josep [24 ]
Coats, Andrew J. S. [7 ]
机构
[1] Univ Birmingham, Inst Cardiovasc Sci, Birmingham, W Midlands, England
[2] Monash Univ, Ctr Cardiovasc Res & Educ Therapeut, Melbourne, Vic, Australia
[3] Univ East Anglia, Fac Med & Hlth Sci, Norwich Med Sch, Norwich, Norfolk, England
[4] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Ctr Stat Med, Oxford, England
[5] Baylor Univ, Med Ctr, Baylor Heart & Vasc Inst, Dallas, TX USA
[6] St Georges Univ London, Cardiovasc & Cell Sci Inst, London, England
[7] IRCCS San Raffaele Pisana, Dept Med Sci, Rome, Italy
[8] Univ Klinikum Saarlandes, Kardiol Angiol & Internist Intens Med, Homburg, Germany
[9] Univ Glasgow, Robertson Inst Biostat, Glasgow, Lanark, Scotland
[10] Univ Glasgow, Clin Trials Unit, Glasgow, Lanark, Scotland
[11] Gothenburg Univ, Sahlgrenska Acad, Wallenberg Lab Cardiovasc Res, Gothenburg, Sweden
[12] Charite Campus Virchow Klinikum, Dept Cardiol, Berlin, Germany
[13] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Rb Groningen, Netherlands
[14] Univ Alcala IRYCIS, Hosp Univ Ramon & Cajal, Dept Internal Med, Plaza San Diego, Madrid, Spain
[15] Oslo Univ Hosp, Dept Cardiol, Oslo, Norway
[16] Univ Hull, Fac Hlth Sci, Hull York Med Sch, Kingston Upon Hull, Yorks, England
[17] Sahlgrens Univ Hosp, Dept Cardiol, Gothenburg, Sweden
[18] Gothenburg Univ, Gothenburg, Sweden
[19] Univ Oslo, Rikshosp Univ Hosp, Oslo, Norway
[20] Univ Oslo, Fac Med, Oslo, Norway
[21] Univ Gothenburg, Sahlgrenska Acad, Hlth Metr, Gothenburg, Sweden
[22] Univ Spital Zurich, Klin Kardiol, Zurich, Switzerland
[23] Univ Glasgow, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland
[24] INCLIVA Biomed Res Inst, Valencia, Spain
关键词
beta-blockers; heart failure; mortality; renal impairment; CARDIAC-INSUFFICIENCY BISOPROLOL; RANDOMIZED INTERVENTION TRIAL; II CIBIS-II; ATRIAL-FIBRILLATION; EJECTION FRACTION; BASE-LINE; CARVEDILOL; SURVIVAL; METOPROLOL; INSIGHTS;
D O I
10.1016/j.jacc.2019.09.059
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND Moderate and moderately severe renal impairment are common in patients with heart failure and reduced ejection fraction, but whether beta-blockers are effective is unclear, leading to underuse of life-saving therapy. OBJECTIVES This study sought to investigate patient prognosis and the efficacy of beta-blockers according to renal function using estimated glomerular filtration rate (eGFR). METHODS Analysis of 16,740 individual patients with left ventricular ejection fraction <50% from 10 double-blind, placebo-controlled trials was performed. The authors report all-cause mortality on an intention-to-treat basis, adjusted for baseline covariates and stratified by heart rhythm. RESULTS Median eGFR at baseline was 63 (interquartile range: 50 to 77) ml/min/1.73 m(2); 4,584 patients (27.4%) had eGFR 45 to 59 ml/min/1.73 m(2), and 2,286 (13.7%) 30 to 44 ml/min/1.73 m(2). Over a median follow-up of 1.3 years, eGFR was independently associated with mortality, with a 12% higher risk of death for every 10 ml/min/1.73 m(2) lower eGFR (95% confidence interval [CI]: 10% to 15%; p < 0.001). In 13,861 patients in sinus rhythm, beta-blockers reduced mortality versus placebo; adjusted hazard ratio (HR): 0.73 for eGFR 45 to 59 ml/min/1.73 m(2) (95% CI: 0.62 to 0.86; p < 0.001) and 0.71 for eGFR 30 to 44 ml/min/1.73 m(2) (95% CI: 0.58 to 0.87; p = 0.001). The authors observed no deterioration in renal function over time in patients with moderate or moderately severe renal impairment, no difference in adverse events comparing beta-blockers with placebo, and higher mortality in patients with worsening renal function on follow-up. Due to exclusion criteria, there were insufficient patients with severe renal dysfunction (eGFR <30 ml/min/1.73 m(2)) to draw conclusions. In 2,879 patients with atrial fibrillation, there was no reduction in mortality with beta-blockers at any level of eGFR. CONCLUSIONS Patients with heart failure, left ventricular ejection fraction <50% and sinus rhythm should receive beta-blocker therapy even with moderate or moderately severe renal dysfunction. (C) 2019 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.
引用
收藏
页码:2893 / 2904
页数:12
相关论文
共 40 条
[1]   PROTEINURIA IN CONGESTIVE HEART-FAILURE [J].
ALBRIGHT, R ;
BRENSILVER, J ;
CORTELL, S .
AMERICAN JOURNAL OF NEPHROLOGY, 1983, 3 (05) :272-275
[2]  
[Anonymous], J AM COLL CARDIOL
[3]   Improved survival with bisoprolol in patients with heart failure and renal impairment: an analysis of the cardiac insufficiency bisoprolol study II (CIBIS-II) trial [J].
Castagno, Davide ;
Jhund, Pardeep S. ;
McMurray, John J. V. ;
Lewsey, James D. ;
Erdmann, Erland ;
Zannad, Faiez ;
Remme, Willem J. ;
Lopez-Sendon, Jose L. ;
Lechat, Philippe ;
Follath, Ferenc ;
Hoglund, Christer ;
Mareev, Viacheslav ;
Sadowski, Zygmunt ;
Seabra-Gomes, Ricardo J. ;
Dargie, Henry J. .
EUROPEAN JOURNAL OF HEART FAILURE, 2010, 12 (06) :607-616
[4]   Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy -: A prospective, placebo-controlled trial [J].
Cice, G ;
Ferrara, L ;
D'Andrea, A ;
D'Isa, S ;
Di Benedetto, A ;
Cittadini, A ;
Russo, PE ;
Golino, P ;
Calabrò, R .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (09) :1438-1444
[5]   Myocardial viability as a determinant of the ejection fraction response to carvedilol in patients with heart failure (CHRISTMAS trial): randomised controlled trial [J].
Cleland, JGF ;
Pennell, DJ ;
Ray, SG ;
Coats, AJ ;
Macfarlane, PW ;
Murray, GD ;
Mule, JD ;
Vered, Z ;
Lahiri, A .
LANCET, 2003, 362 (9377) :14-21
[6]   Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials [J].
Cleland, John G. F. ;
Bunting, Karina V. ;
Flather, Marcus D. ;
Altman, Douglas G. ;
Holmes, Jane ;
Coats, Andrew J. S. ;
Manzano, Luis ;
McMurray, John J. V. ;
Ruschitzka, Frank ;
van Veldhuisen, Dirk J. ;
von Lueder, Thomas G. ;
Bohm, Michael ;
Andersson, Bert ;
Kjekshus, John ;
Packer, Milton ;
Rigby, Alan S. ;
Rosano, Giuseppe ;
Wedel, Hans ;
Hjalmarson, Ake ;
Wikstrand, John ;
Kotecha, Dipak .
EUROPEAN HEART JOURNAL, 2018, 39 (01) :26-35
[7]   Efficacy and safety of nebivolol in elderly heart failure patients with impaired renal function: insights from the SENIORS trial [J].
Cohen-Solal, Alain ;
Kotecha, Dipak ;
van Veldhuisen, Dirk J. ;
Babalis, Daphne ;
Boehm, Michael ;
Coats, Andrew J. ;
Roughton, Michael ;
Poole-Wilson, Philip ;
Tavazzi, Luigi ;
Flather, Marcus .
EUROPEAN JOURNAL OF HEART FAILURE, 2009, 11 (09) :872-880
[8]   The kidney in heart failure: an update [J].
Damman, Kevin ;
Testani, Jeffrey M. .
EUROPEAN HEART JOURNAL, 2015, 36 (23) :1437-+
[9]   Current Evidence on Treatment of Patients With Chronic Systolic Heart Failure and Renal Insufficiency [J].
Damman, Kevin ;
Tang, W. H. Wilson ;
Felker, G. Michael ;
Lassus, Johan ;
Zannad, Faiez ;
Krum, Henry ;
McMurray, John J. V. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (09) :853-871
[10]   Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis [J].
Damman, Kevin ;
Valente, Mattia A. E. ;
Voors, Adriaan A. ;
O'Connor, Christopher M. ;
van Veldhuisen, Dirk J. ;
Hillege, Hans L. .
EUROPEAN HEART JOURNAL, 2014, 35 (07) :455-+